Which doctor should you consult for Mounjaro in India?

Two more facts before we begin: expect a pre-prescription blood panel (HbA1c, lipids, thyroid, kidney, liver) costing roughly ₹1,500–₹3,500, and remember the approved label — BMI ≥30, or BMI ≥27 with at least one weight-related condition. Your doctor confirms eligibility, not a website.

In Kaivo's May 2026 analysis of 3,001 posts and comments on r/GLP1India — the largest Indian GLP-1 community — finding a doctor was the second-most-discussed topic (238 mentions), ahead of price (143) and side effects (115). The drug itself is everywhere: Mounjaro became one of India's top-selling pharmaceutical brands within months of its March 2025 launch. The bottleneck isn't the medicine. It's the consultation room.

This page solves the consultation room.

Who can prescribe Mounjaro in India?

Here is who actually writes these prescriptions, and when each makes sense:

Two practical realities the table doesn't show. First, endocrinologists are scarce — DM Endocrinology seats in India number in the dozens per year, so qualified endos concentrate in metro private hospitals with appointment waits of two to six weeks. Second, familiarity beats specialty. A diabetologist who has titrated fifty patients on tirzepatide is a better first consult than a senior specialist who has never initiated it for weight loss.

Endocrinologist vs GP vs online — which should you book?

A simple decision path:

1. You have type 2 diabetes, uncontrolled thyroid disease, or PCOS with metabolic complications → endocrinologist (in clinic or online). Mounjaro is approved for type 2 diabetes too, and dose decisions interact with your existing medication.
2. You're broadly healthy, BMI 27+, and have a GP you trust → start there. If they're comfortable with GLP-1s, you're done in one visit. If not, ask for a referral rather than a verdict.
3. You've been putting this off because of cost, queues, distance, or the fear of being lectured → a structured online consultation is built for exactly this. The prescription is legally identical; the experience is private; follow-ups don't cost you a half-day of leave.

One myth to retire: there is no "Mounjaro specialist licence" in India. A prescription from a video consultation with an MBBS-registered doctor is as valid at the pharmacy counter as one from a corporate hospital's endocrinology department.

How much does a doctor consultation for Mounjaro cost in India?

Budget for the whole journey, not one visit. GLP-1 therapy means dose reviews roughly every four weeks during titration — five or six touchpoints in the first six months. At ₹1,500–₹2,000 per hospital visit, standalone follow-ups quietly add ₹8,000–₹12,000 to year one. This is the line item bundled programmes exist to remove. (The medicine itself is the bigger number — Mounjaro KwikPen runs roughly ₹13,000–₹26,000 per month at MRP depending on dose, and generic semaglutide now starts near ₹1,300 a month — see our GLP-1 cost guide for India for the full table.)

What tests will the doctor order before prescribing Mounjaro?

Just as important is the history screen — the questions are not small talk:

1. Personal or family history of medullary thyroid carcinoma or MEN 2 → tirzepatide is contraindicated.
2. Pregnancy, planning pregnancy, or breastfeeding → not prescribed.
3. History of pancreatitis → prescribed only with caution and discussion.
4. Severe gut disorders (e.g. gastroparesis) → usually avoided.

A doctor who asks all of this is not creating friction. A seller who asks none of it is the actual risk — more on that below.

"He laughed and wrote me a diet" — what to do when a doctor refuses

Those words in the heading are a real patient's words from r/GLP1India. So are "doctor might laugh me out" and "find one who is open minded." In our analysis, this experience — being dismissed, lectured, or handed a photocopied diet chart — is the single most common reason Indians delay treatment they're eligible for.

Some context that helps you not take it personally: obesity medicine is young in India. Many physicians trained in an era when "eat less, walk more" was the entire toolkit, and a 30-minute OPD queue doesn't reward nuance. But the science has formally moved. India's revised obesity guidelines (January 2025) — developed by Indian experts alongside The Lancet Diabetes & Endocrinology Commission — classify obesity as a chronic disease in two stages, starting at BMI above 23 for Indians, with Stage 2 (excess weight plus a related condition or functional limitation) explicitly warranting intensive treatment, including medication. "Come back after you've tried harder" is no longer the guideline-backed answer for Stage 2 patients.

Meanwhile, the approved label for tirzepatide in weight management is BMI ≥30, or BMI ≥27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease). If you sit inside those criteria, you are not asking for a favour — you are asking for a licensed, indicated therapy.

What to actually say — three scripts that keep the conversation clinical:

1. Opening the topic: "I've attempted structured diet and exercise for [X] months — here's what happened. My BMI is [Y] and I have [condition]. I'd like to discuss whether GLP-1 therapy such as tirzepatide is appropriate for me, and which tests you'd want first." You've framed it as a medical evaluation, not a product request.
2. After a dismissive response: "I understand. Is your concern a specific contraindication in my case, or a general preference for lifestyle-first? If it's the latter, I'd appreciate a referral to a doctor who practises obesity medicine." Doctors document referrals; "no" without reasons rarely survives this question.
3. If you're starting online instead: have your weight history, current medicines, family history and any old lab reports ready before the video call. The consult goes from interrogation to collaboration.

What not to do: don't hide your medical history to get a yes — the contraindication screen is what keeps this drug safe for you — and don't chase any channel that skips the screen entirely. A doctor saying "not yet, let's check your thyroid first" is doing the job. A Telegram seller saying "no prescription needed, COD available" is not a shortcut; in India that sale is illegal, and counterfeit pens are exactly how people get hurt (here's how to spot a fake Mounjaro pen).

Is it legal to get Mounjaro prescribed through an online consultation in India?

What the law actually establishes, in plain terms:

1. Who may consult: any Registered Medical Practitioner (MBBS or above, enrolled on the Indian Medical Register or a State Medical Register). The first consult does not need to be in person.
2. Mode: for prescribing a therapy like this, the consultation should be a video consult — the doctor must be able to assess you properly, and carries the same professional accountability as an in-person visit.
3. The prescription: sent digitally (PDF, email, app) with the doctor's name, qualifications, registration number, signature and date. That e-prescription is legally valid at any pharmacy, online or offline.
4. What's excluded: Schedule X drugs and substances under the NDPS Act. GLP-1 medicines are Schedule H — prescription-required, tele-prescribable.

How to verify any online doctor in 60 seconds: take the registration number from the prescription and search it on the National Medical Commission's Indian Medical Register (nmc.org.in) or the relevant State Medical Council register. A legitimate platform will display its doctors' names, qualifications and registration numbers before you pay — at Kaivo, you'll find our doctors' full credentials on every page.

And the bright legal line worth repeating: a website offering Mounjaro without any prescription isn't a convenience — it's breaking the Drugs and Cosmetics Act, and is statistically where counterfeits live. The prescription step is not the obstacle. It's the product.

"I live alone in Bangalore, can't tell my family" — privacy, stigma, and judgment-free care

In our community analysis, 22 posts explicitly described hiding treatment from family, or fearing their reaction — parents who'd call it vanity, in-laws who'd call it laziness, colleagues who'd have opinions. One line stayed with us: "I live alone in Bangalore, can't tell my family — online consultations work for me."

So let's say the quiet part clearly. Choosing medical treatment for a medical condition is not a confession, and you don't owe anyone an explanation — not your family, not your office, not the pharmacist's queue. The only person who needs your complete, honest history is your doctor, because that's what keeps the treatment safe.

If in-clinic visits are what's stopping you — the waiting room, the weighing scale in public, the relative who might spot you at the hospital — telehealth removes every one of those moments. The consult happens where you choose. The records stay between you and your care team. The follow-ups are a video call, not an outing to explain.

That isn't secrecy. That's dignity, and it's how a fair amount of modern medicine is now delivered.

How a Kaivo doctor consultation works

Kaivo is a doctor-led weight-loss programme built for exactly the problems on this page — finding a physician who treats obesity seriously, without the queue, the lecture, or the audience.

1. Medical intake online. Your history, goals, current medicines and any past reports — reviewed by a physician before anyone talks dosing.
2. Video consultation with a physician who practises obesity medicine. Founding clinicians Dr. Rinku Sarmah (MBBS, MD Internal Medicine, AIIMS-trained) and Dr. Harshit Anand (MBBS, MD Internal Medicine, AIIMS-trained) built the protocol; the consult is unhurried and judgment-free by design.
3. Labs arranged from home. Baseline panel with home collection — the same tests in the table above, without a hospital trip.
4. E-prescription only if you're eligible. If GLP-1 therapy isn't right for you, the doctor tells you that too — and what is.
5. No medication markup. Kaivo doesn't sell or bundle the drug. Your prescription is filled by a separate licensed pharmacy at market price, which means the medical advice has no sales incentive behind it.
6. Titration follow-ups included. Dose reviews, side-effect management, and a maintenance plan from day one — because the prescription is the start of the work, not the end. (And when weight loss stalls, the same doctor reads the plateau and plans the next step.)

If you've read this far because some version of "the doctor might laugh at me" has kept you waiting: book a consultation with a Kaivo physician. The judgment-free part isn't marketing copy — it's the reason the company exists.

Sources

1. Telemedicine Practice Guidelines, Board of Governors (MCI) / Ministry of Health & Family Welfare, 25 March 2020 — Appendix 5 to the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002.
2. National Medical Commission — Indian Medical Register (doctor verification), nmc.org.in.
3. Revised definitions and treatment framework for obesity in Asian Indians, January 2025 — Indian adaptation of The Lancet Diabetes & Endocrinology Commission; Diabetes & Metabolic Syndrome: Clinical Research & Reviews (Misra et al.).
4. Eli Lilly — Mounjaro (tirzepatide) India launch (March 2025) and KwikPen launch (August 2025); CDSCO-approved prescribing information.
5. Business Standard / Reuters — "Mounjaro KwikPen by Lilly debuts in India at ₹14,000," 13 August 2025.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022.
7. Kaivo Research — Analysis of 3,001 posts and comments, r/GLP1India, May 2026 (doctor-access, cost and stigma mention counts).
8. Drugs and Cosmetics Act, 1940 and Rules, 1945 — Schedule H and Schedule X provisions.